Is Cencora, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Cencora, Inc. has moved from very expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key valuation ratios include a P/E ratio of 44, an EV to EBITDA of 20.00, and a Price to Book Value of 78.87. In comparison, Boston Scientific Corp. has a P/E of 73.71 and an EV to EBITDA of 45.38, while McKesson Corp. shows a P/E of 57.25 and an EV to EBITDA of 37.15, indicating that Cencora is positioned more favorably relative to these peers.
Cencora's stock has significantly outperformed the S&P 500, with a year-to-date return of 44.51% compared to the S&P 500's 13.30%, reinforcing the notion that the stock is fairly valued given its strong performance metrics.